INVO Fertility, Inc. (IVF) announced the issuance of a U.S. patent covering a modified version of its proprietary INVOcell device. The patent became effective on February 10, 2026, extending intellectual property protection through 2040.
The INVOcell device is the world's first FDA-cleared intravaginal culture (IVC) system, enabling fertilization and early embryo development to occur within a woman's body. The newly patented modification incorporates a simplified design with a single main chamber, developed based on clinical feedback, to enhance usability in assisted reproductive care.
The company announced a 1-for-8 reverse stock split on November 28, 2025.
IVF is currently trading at $1.21, up 9.08%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.